{"url_path":"/sec/rkda/8-k/2026-07-02/item-5-08","section_key":"item-5-08","section_title":"Item 5.08 Shareholder Director Nominations","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-294619-index.html","accession_number":"0001193125-26-294619","cik":"0001469443","ticker":"RKDA","issuer_name":"Arcadia Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-294619-index.html","primary_entity_key":"0001469443","primary_entity_name":"Arcadia Biosciences, Inc."},"word_count":450,"has_tables":true,"body_markdown":"## Item 5.08 Shareholder Director Nominations\n\nThe Board has determined that the Company’s 2026 annual meeting of stockholders will be held on September 10, 2026 (the “2026 Annual Meeting”). The time and location of the 2026 Annual Meeting, and the matters to be considered, will be as set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting to be filed with the Securities and Exchange Commission (the \"SEC\").\n\n \n\nBecause the expected date of the 2026 Annual Meeting represents a change of more than 30 calendar days from the date of the anniversary of the Company’s 2025 annual meeting of stockholders, the Company is informing stockholders of this change and the updated deadlines for stockholders to submit qualified proposals intended for inclusion in our proxy statement or nominations for director, or other proposals for consideration at the 2026 Annual Meeting, in accordance with the rules and regulations of the SEC, including without limitation stockholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the Company’s Bylaws. Accordingly, to be timely, stockholders wishing to nominate a candidate for director or wishing to submit\n\n \n\n \n\nproposals intended to be considered for inclusion in our proxy statement relating to the 2026 Annual Meeting, or other proposals for consideration at the 2026 Annual Meeting, must ensure that proper notice is received by the Company at its offices no later than the close of business on July 13, 2026, which is at least 10 days after the filing date of this Report on Form 8-K, which we consider a reasonable time before we will begin printing and mailing proxy materials, and which is provided for in our Bylaws. In addition, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Securities Exchange Act of 1934, as amended, by the close of business on July 13, 2026. Any proposal intended to be considered for inclusion in our proxy statement must comply with Rule 14a-8 of Regulation 14A of the proxy rules of the SEC. The submission of a stockholder proposal does not guarantee that it will be included in the Company’s proxy materials or that it will be considered to be a qualified proposal for consideration at the 2026 Annual Meeting. The Company’s Bylaws specify requirements relating to the content of the notice that stockholders must provide, and any such notices must be received in writing at the following address: Arcadia Biosciences, Inc., 5956 Sherry Lane, 20th Floor, Dallas, Texas 75225, Attention: Corporate Secretary. The notice must comply with the procedures and include the information required by the Company’s Bylaws."}